http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 14:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+SUSQUEHANNA+SECURITIES%2C+LLC/26928721.html si-local-file:///var/storage/secattach/20260814/26928721.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+SUSQUEHANNA+SECURITIES%2C+LLC/26928721.html Fri, 14 Aug 2026 14:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+SUSQUEHANNA+SECURITIES%2C+LLC/26928721.html si-local-file:///var/storage/secattach/20260814/26928721.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+SUSQUEHANNA+SECURITIES%2C+LLC/26928721.html Fri, 14 Aug 2026 14:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+SUSQUEHANNA+SECURITIES%2C+LLC/26928721.html si-local-file:///var/storage/secattach/20260814/26928721.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+SUSQUEHANNA+SECURITIES%2C+LLC/26928721.html Fri, 14 Aug 2026 14:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+10/26897631.html si-local-file:///var/storage/secattach/20260810/26897631.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+10/26897631.html Mon, 10 Aug 2026 16:04:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+10/26897631.html si-local-file:///var/storage/secattach/20260810/26897631.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+10/26897631.html Mon, 10 Aug 2026 16:04:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+10/26897631.html si-local-file:///var/storage/secattach/20260810/26897631.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+10/26897631.html Mon, 10 Aug 2026 16:04:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/Analyst+PT+Change/Purple+Biotech+Ltd.+%28PPBT%29+PT+Lowered+to+%2417+at+H.C.+Wainwright/26893935.html (Updated - August 10, 2026 6:53 AM EDT) <p>H.C. Wainwright analyst Emily Bodnar lowered the price target on Purple Biotech Ltd. (NASDAQ: PPBT) to $17.00 (from $30.00) while maintaining a Buy rating.</p><p>The analyst commented: "This morning, Purple reported 2Q26 earnings and provided a corporate update, highlighting preclinical progress for its lead CAPTN-3 tri-specific T cell engager (TCE) programs. Recent data from a tox NHP study for CAPTN-3 masking were presented at EACR 2026 (see poster here) in June showing IM1240 (cappedCD3×5T4×NKG2A) led to apoptosis of PD-1-resistant tumor cells in a neo. adj. chemo + anti-PD-1 resistant metastatic lymph node HNSCC (n=6) http://www.streetinsider.com/Analyst+PT+Change/Purple+Biotech+Ltd.+%28PPBT%29+PT+Lowered+to+%2417+at+H.C.+Wainwright/26893935.html Mon, 10 Aug 2026 06:53:18 -0400 PPBT http://www.streetinsider.com/Analyst+Comments/Purple+Biotech+Ltd.+%28PPBT%29+PT+Lowered+to+%2417+at+H.C.+Wainwright/26893935.html (Updated - August 10, 2026 6:53 AM EDT) <p>H.C. Wainwright analyst Emily Bodnar lowered the price target on Purple Biotech Ltd. (NASDAQ: PPBT) to $17.00 (from $30.00) while maintaining a Buy rating.</p><p>The analyst commented: "This morning, Purple reported 2Q26 earnings and provided a corporate update, highlighting preclinical progress for its lead CAPTN-3 tri-specific T cell engager (TCE) programs. Recent data from a tox NHP study for CAPTN-3 masking were presented at EACR 2026 (see poster here) in June showing IM1240 (cappedCD3×5T4×NKG2A) led to apoptosis of PD-1-resistant tumor cells in a neo. adj. chemo + anti-PD-1 resistant metastatic lymph node HNSCC (n=6) http://www.streetinsider.com/Analyst+Comments/Purple+Biotech+Ltd.+%28PPBT%29+PT+Lowered+to+%2417+at+H.C.+Wainwright/26893935.html Mon, 10 Aug 2026 06:53:18 -0400 PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+07/26887382.html si-local-file:///var/storage/secattach/20260807/26887382.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+07/26887382.html Fri, 07 Aug 2026 07:03:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+07/26887382.html si-local-file:///var/storage/secattach/20260807/26887382.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+07/26887382.html Fri, 07 Aug 2026 07:03:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+07/26887382.html si-local-file:///var/storage/secattach/20260807/26887382.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Aug+07/26887382.html Fri, 07 Aug 2026 07:03:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jul+29/26834921.html si-local-file:///var/storage/secattach/20260729/26834921.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jul+29/26834921.html Wed, 29 Jul 2026 16:06:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jul+29/26834921.html si-local-file:///var/storage/secattach/20260729/26834921.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jul+29/26834921.html Wed, 29 Jul 2026 16:06:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jul+29/26834921.html si-local-file:///var/storage/secattach/20260729/26834921.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jul+29/26834921.html Wed, 29 Jul 2026 16:06:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+23/26677181.html si-local-file:///var/storage/secattach/20260623/26677181.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+23/26677181.html Tue, 23 Jun 2026 09:29:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+23/26677181.html si-local-file:///var/storage/secattach/20260623/26677181.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+23/26677181.html Tue, 23 Jun 2026 09:29:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+23/26677181.html si-local-file:///var/storage/secattach/20260623/26677181.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+23/26677181.html Tue, 23 Jun 2026 09:29:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+11/26632495.html si-local-file:///var/storage/secattach/20260611/26632495.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+11/26632495.html Thu, 11 Jun 2026 07:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+11/26632495.html si-local-file:///var/storage/secattach/20260611/26632495.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+11/26632495.html Thu, 11 Jun 2026 07:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+11/26632495.html si-local-file:///var/storage/secattach/20260611/26632495.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Jun+11/26632495.html Thu, 11 Jun 2026 07:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html <p>Purple Biotech Ltd. (NASDAQ/TASE: PPBT) presented preclinical data for its lead candidate IM1240 at the European Association for Cancer Research 2026 Annual Congress held June 8-11 in Budapest, Hungary.</p> <p>The company reported results from a non-human primate toxicology study showing IM1240 demonstrated an 8-fold longer half-life and 16-fold greater exposure compared to a non-capped variant. The study found IM1240 induced minimal cytokine release at 10 mg/kg dose, while the non-capped version triggered robust cytokine release at 0.03 mg/kg.</p> <p>In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html Thu, 11 Jun 2026 07:01:09 -0400 A.23636062 A.50215584 O.07128796 O.11009544 O.41740509 PPBT http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html <p>Purple Biotech Ltd. (NASDAQ/TASE: PPBT) presented preclinical data for its lead candidate IM1240 at the European Association for Cancer Research 2026 Annual Congress held June 8-11 in Budapest, Hungary.</p> <p>The company reported results from a non-human primate toxicology study showing IM1240 demonstrated an 8-fold longer half-life and 16-fold greater exposure compared to a non-capped variant. The study found IM1240 induced minimal cytokine release at 10 mg/kg dose, while the non-capped version triggered robust cytokine release at 0.03 mg/kg.</p> <p>In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html Thu, 11 Jun 2026 07:01:09 -0400 A.23636062 A.50215584 O.07128796 O.11009544 O.41740509 PPBT http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html <p>Purple Biotech Ltd. (NASDAQ/TASE: PPBT) presented preclinical data for its lead candidate IM1240 at the European Association for Cancer Research 2026 Annual Congress held June 8-11 in Budapest, Hungary.</p> <p>The company reported results from a non-human primate toxicology study showing IM1240 demonstrated an 8-fold longer half-life and 16-fold greater exposure compared to a non-capped variant. The study found IM1240 induced minimal cytokine release at 10 mg/kg dose, while the non-capped version triggered robust cytokine release at 0.03 mg/kg.</p> <p>In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html Thu, 11 Jun 2026 07:01:09 -0400 A.23636062 A.50215584 O.07128796 O.11009544 O.41740509 PPBT http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html <p>Purple Biotech Ltd. (NASDAQ/TASE: PPBT) presented preclinical data for its lead candidate IM1240 at the European Association for Cancer Research 2026 Annual Congress held June 8-11 in Budapest, Hungary.</p> <p>The company reported results from a non-human primate toxicology study showing IM1240 demonstrated an 8-fold longer half-life and 16-fold greater exposure compared to a non-capped variant. The study found IM1240 induced minimal cytokine release at 10 mg/kg dose, while the non-capped version triggered robust cytokine release at 0.03 mg/kg.</p> <p>In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html Thu, 11 Jun 2026 07:01:09 -0400 A.23636062 A.50215584 O.07128796 O.11009544 O.41740509 PPBT http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html <p>Purple Biotech Ltd. (NASDAQ/TASE: PPBT) presented preclinical data for its lead candidate IM1240 at the European Association for Cancer Research 2026 Annual Congress held June 8-11 in Budapest, Hungary.</p> <p>The company reported results from a non-human primate toxicology study showing IM1240 demonstrated an 8-fold longer half-life and 16-fold greater exposure compared to a non-capped variant. The study found IM1240 induced minimal cytokine release at 10 mg/kg dose, while the non-capped version triggered robust cytokine release at 0.03 mg/kg.</p> <p>In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment http://www.streetinsider.com/FDA/Purple+Biotech+presents+IM1240+preclinical+data+at+EACR+conference/26632455.html Thu, 11 Jun 2026 07:01:09 -0400 A.23636062 A.50215584 O.07128796 O.11009544 O.41740509 PPBT